DRMA: Dermata Price to Sales

Symbol and logo of brand Dermata Corp (DRMA)

The price-to-sales ratio demonstrates the market valuation of Dermata Therapeutics (DRMA), where the value is fixed at 46.70. The scientific team is developing a unique drug delivery platform to combat rosacea and acne. Dermata Therapeutics (DRMA) is creating innovative topical agents based on freshwater sponges, currently undergoing FDA reviews. Patents for a mechanical therapy method provide a competitive advantage, determining the future profitability of the business.

DRMA: Dermata Therapeutics, Inc. Price-to-Revenue Ratio 11/12/2026 - 11/13/2026

Dermata (DRMA) - metric breakdowns and financial figures

- stock price and consensus target price:
Share Price dermatarx.com|DRMA - Analyst Consensus Forecast
- market capitalization information:
Market Value Dermata|DRMA - Total Company Value
- shareholders' equity book value data:
Accounting Value of a Share Dermata Therapeutics|DRMA - Company Book Value|Market Cap to Net Assets Ratio dermatarx.com|DRMA - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Dermata Therapeutics|DRMA - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Dermata Corp|DRMA - Company Aggregate Debts|Debts to Book Capitalization Dermata|DRMA - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Dermata Therapeutics|Intermediate Liquidity Ratio dermatarx.com
- earnings and valuation multiples information:
DRMA - Net Profit|Expected Net Income Dermata Therapeutics|DRMA - P/E Multiple|Projected Price to Earnings Ratio Dermata Therapeutics Inc|DRMA - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Dermata|DRMA - Operating profit EBITDA|Net earnings per share (EPS TTM) Dermata Therapeutics|DRMA - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months dermatarx.com|DRMA - Earnings growth in current year|Expected net earnings per share growth next year Dermata Therapeutics
- total revenue and sales volume data:
DRMA - Company Sales|Projected Sales Volume dermatarx.com|DRMA - Market Cap to Revenue|Price to Expected Revenue Ratio Dermata
General company analysis:DRMA dermatarx.com
Signature product of Dermata Therapeutics Inc

Dermata Therapeutics' reputation for developing safe acne and rosacea treatments drives high brand equity, which investors evaluate via the price-to-sales ratio. This metric measures the cost per unit of revenue, allowing the P/S levels on the chart to determine the asset's degree of overvaluation and identify the exhaustion of business growth drivers in a timely manner.

Who Dermata Therapeutics competes with

krystalbio.com - Market Cap to Revenue Ratio|P/S Multiple APGE (Apogee Therapeutics, Inc.)|Arcutis (ARQT) - Price to Sales|VCEL - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ORKA (Oruka Pharma)|sanaramedtech.com (SMTI) - Price-to-Revenue Ratio|Market Cap to Revenue DBV Technologies|SLSN (Solesence Beauty) - P/S Multiple|P/S Multiple Journey Medical Corp.|Market Cap to Revenue FBRX (Forte Biosciences, Inc)|Market Cap to Sales Volume EMPG|P/S Multiple SLGL (Sol-Gel Technologies)|P/S Multiple AXIL Brands Inc AXIL|MDCX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio VRCA (Verrica Pharmaceuticals)|HOTH (hoththerapeutics.com) - Market Cap to Revenue|BFRI: Market Cap to Sales Volume|VYNE (VYNE Therapeutics, Inc.) - P/S Multiple|SNOA: Market Capitalization-to-Revenue Ratio|P/S Multiple QNRX|AZTR - Price to Sales|Price-to-Revenue Ratio Elevai Skincare ELAB|Market Capitalization-to-Revenue Ratio RVNC